Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 3,305 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diseases of the Circulatory System Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Assess AER-271

NCT03804476
View directory record Official record
Conditions
Stroke, Stroke, Acute, Stroke, Ischemic
Interventions
AER-271, Placebo
Drug
Lead sponsor
Aeromics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 3 Interventional Results available

Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

NCT00781391
View directory record Official record
Conditions
Stroke, Atrial Fibrillation, Embolism
Interventions
warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg), placebo warfarin, placebo edoxaban
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
21 Years and older
Enrollment
21,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
316
States / cities
Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 308 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

NCT00738062
View directory record Official record
Conditions
Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
44
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 17, 2026, 2:36 AM EDT
Completed No phase listed Observational Results available

Post-Market CorPath Registry on the CorPath 200 System in Percutaneous Coronary Interventions

NCT01917682
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases
Interventions
CorPath-assisted Percutaneous Coronary Intervention
Procedure
Lead sponsor
Siemens Healthineers Endovascular Robotics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
15
States / cities
San Diego, California • Glenwood Springs, Colorado • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 3 Interventional

Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.

NCT00047580
View directory record Official record
Conditions
Multiple Sclerosis, Muscle Spasticity, Spinal Cord Injury, Stroke
Interventions
tizanidine hydrochloride capsule
Drug
Lead sponsor
Elan Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
16
States / cities
Tucson, Arizona • Encinitas, California • Northridge, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 17, 2026, 2:36 AM EDT
Completed No phase listed Observational

Rhythm Express Wearable System vs. Simultaneous Polysomnography for the Diagnosis of Obstructive Sleep Apnea in Adults With Suspected or Observed Atrial Fibrillation

NCT06907888
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA), Atrial Fibrillation (Paroxysmal), Palpitations
Interventions
Rhythm Express Wearable System
Device
Lead sponsor
VivaQuant
Industry
Eligibility
21 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Conway, Arkansas • St Louis, Missouri • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 17, 2026, 2:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Swab Sample Collection for the Detection of Bacterial Proteases in Wounds Assay

NCT01750203
View directory record Official record
Conditions
Chronic Wounds With Different Etiologies
Interventions
Swabs
Other
Lead sponsor
Systagenix Wound Management
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

NCT06785454
View directory record Official record
Conditions
Obstructive Sleep Apnea, Hypertension
Interventions
Lorundrostat, Placebo
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
27
States / cities
Tuscaloosa, Alabama • Chandler, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

NCT00024466
View directory record Official record
Conditions
Multiple Myeloma
Interventions
GVAX, Autologous transplant
Biological · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 17, 2026, 2:36 AM EDT
Withdrawn Phase 4 Interventional

Blood Pressure Lowering in Acute Stroke Trial

NCT01400256
View directory record Official record
Conditions
Stroke, Acute
Interventions
Valsartan
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Early Phase 1 Interventional Results available

New Tool to Enhance Post-stroke Upper Extremity Disability

NCT05277389
View directory record Official record
Conditions
Stroke
Interventions
START - Startle Adjuvant Rehabilitation Therapy, Sham Control
Other
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Results available

CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

NCT00091260
View directory record Official record
Conditions
Multiple Myeloma
Interventions
dexamethasone, lenalidomide
Drug
Lead sponsor
Vaishali Sanchorawala
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Not applicable Interventional

AI ENRICH - AI Detection of ICH

NCT03865979
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Viz RECRUIT
Device
Lead sponsor
Viz.ai, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Little Rock, Arkansas • Evanston, Illinois • Camden, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 17, 2026, 2:36 AM EDT
Not yet recruiting Phase 3 Interventional

A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

NCT07728188
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
Etentamig, Pomalidomide, Daratumumab, Dexamethasone, Carfilzomib, Teclistamab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
24
States / cities
Tucson, Arizona • Cerritos, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Not applicable Interventional Results available

Randomized DB Controlled Trial of Botulinum Toxin A in Hemiplegic Shoulder Pain and Spasticity

NCT00661089
View directory record Official record
Conditions
Post-stroke Shoulder Pain and Spasticity
Interventions
Botulinum Toxin Type A - OnabotulinumtoxinA, Placebo (Saline)
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 17, 2026, 2:36 AM EDT
Completed No phase listed Observational

A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat

NCT04150289
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Farydak
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Indianapolis, Indiana • Las Vegas, Nevada • Charlotte, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

NCT03984097
View directory record Official record
Conditions
Multiple Myeloma
Interventions
TAK-079, Lenalidomide, Dexamethasone, Bortezomib, Pomalidomide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Birmingham, Alabama • Monterey, California • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Not applicable Interventional

The Safety and Tolerability of an Aerobic and Resistance Exercise Program With Cognitive Training Post-stroke

NCT02272426
View directory record Official record
Conditions
Cerebral Stroke
Interventions
CARET, CTI, Sham CARET, Sham CTI
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Oct 17, 2026, 2:36 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The EBC Recovery Study

NCT04712591
View directory record Official record
Conditions
Traumatic Brain Injury, Intracerebral Haemorrhage, Subarachnoid Haemorrhagic Stroke
Interventions
Auditory stimuli
Diagnostic Test
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
2
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 17, 2026, 2:36 AM EDT
Completed No phase listed Observational

Emulation of the SOUL Diabetes Trial in Healthcare Claims

NCT06659718
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Oral semaglutide, Sitagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
43,650 participants
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 1 Interventional

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

NCT01440582
View directory record Official record
Conditions
Myeloma
Interventions
Panobinostat, Bortezomib, Lenalidomide, Dexamethasone, Symptom Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 17, 2026, 2:36 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Effect of Blueberry Powder Supplementation on Cardiovascular Risk Factors in Subjects With the Metabolic Syndrome

NCT01399138
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Blueberry Powder
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant

NCT00068718
View directory record Official record
Conditions
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma
Interventions
Therapeutic Allogeneic Lymphocytes
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the Amigo Robotic System for Ablation of the Cavo-Tricuspid Isthmus

NCT02467179
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Amigo™ Robotic Catheter Manipulation, Manual Catheter Manipulation
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 17, 2026, 2:36 AM EDT